TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges

Reviews on Recent Clinical Trials
Anita C BellailChunhai Hao

Abstract

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is normally expressed in the human immune system and plays a critical role in antitumor immunity. TRAIL interacts with the death receptors, DR4 and DR5, and activates intracellular apoptotic pathway in cancer cells. This discovery has resulted in a rapid development of cancer therapeutic agents that can activate this apoptotic pathway. These therapeutic agents include recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody (MAb) against DR4 and DR5. Phase I trials have established the safety and tolerability of these TRAIL agonists in patients. Phase II trials are currently evaluating the therapeutic efficacy of TRAIL agonists as single agents or in combination with established cancer therapeutics. This review outlines the advances and the challenges in the development of these TRAIL agonists as effective clinical cancer therapeutics.

Citations

Aug 31, 2011·Apoptosis : an International Journal on Programmed Cell Death·Ling QiChunhai Hao
May 5, 2012·Apoptosis : an International Journal on Programmed Cell Death·Henriette KauntzFrancis Raul
Sep 23, 2011·Cellular and Molecular Neurobiology·Yanli NiuJinbo Deng
Apr 6, 2012·Archives of Pharmacal Research·Soo-Yeon KimHyo-Jeong Kuh
Sep 22, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Meng LiDexian Zheng
Dec 17, 2009·World Journal of Gastroenterology : WJG·Bruno-Christian KoehlerHenning Schulze-Bergkamen
Oct 24, 2009·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Ladislav Andera
May 30, 2015·Biometrika·Sihai Dave ZhaoHongzhe Li
Jan 19, 2013·Cellular and Molecular Life Sciences : CMLS·Nor Saadah M Azahri, Mary M Kavurma
May 19, 2012·Expert Review of Anticancer Therapy·Anita C Bellail, Chunhai Hao
Sep 10, 2015·Oncology Reports·Uddin Md Nazim, Sang-Youel Park
Mar 31, 2015·Oncology Reports·Uddin Md NazimSang-Youel Park
Oct 17, 2012·Biochemical and Biophysical Research Communications·So Jung ParkDong-Hyung Cho
Apr 24, 2012·Hematology/oncology Clinics of North America·Mark J Adler, Dimiter S Dimitrov
Sep 8, 2010·Cancer Letters·Dwayne G Stupack
Feb 9, 2010·Trends in Molecular Medicine·Stefan Grimm, Mathieu Noteborn
Jul 6, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jing ZhitaoWu Anhua
Dec 19, 2009·Biochemical and Biophysical Research Communications·Guo-Ting PeiWan-Wan Lin
Dec 23, 2009·Experimental Cell Research·Zafar Mahmood, Yogeshwer Shukla
Oct 20, 2009·European Journal of Pharmacology·Mathieu H M Noteborn
May 20, 2015·ACS Biomaterials Science & Engineering·Asiri Ediriwickrema, W Mark Saltzman
May 20, 2015·Scientific Reports·Jiahe LiMichael R King
Dec 1, 2010·Oral Diseases·J BunekY L Kapila

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

International Journal of Radiation Oncology, Biology, Physics
John H MaduroAte G J van der Zee
Expert Opinion on Therapeutic Targets
Junaid Abdulghani, Wafik S El-Deiry
© 2021 Meta ULC. All rights reserved